Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Completed
CT.gov ID
NCT02035735
Collaborator
(none)
93
1
1
45
2.1

Study Details

Study Description

Brief Summary

The aim of this study is to prospectively determine if the use of NBI endoscopy modifies the superficial extension of these tumors.

Condition or Disease Intervention/Treatment Phase
  • Procedure: WL and NBI
N/A

Detailed Description

Several studies have already showed the interest of the use of NBI for the early diagnosis of malignancies of the upper aerodigestive tract. For all tumors, the most accurate evaluation of its limits is very important to perform the best strategy of treatment. If surgery seems to be the best option, surgical margins must be widely healthy. Despite the systematic transnasal flexible endoscopy with white lamp followed by laryngoscopy under general anesthesia (LGA) and tomodensitometric evaluation, surgical margins can be unhealthy (in situ carcinoma or dysplasia). We propose to evaluate if the use of the NBI could be useful to determine the superficial spread of squamous cell carcinomas in these locations.

To April 2013 to Mars 2015, all patients with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx and whom a LGA are expected, are included. The day before the LGA, two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light and the second one with NBI. All results are noted on a schema. Superficial extension or synchronous lesions showed by NBI are analysed and compared with with lamp technic.

After surgery, surgical margins were evaluated and healthy margins were measured.

Study Design

Study Type:
Interventional
Actual Enrollment :
93 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Usefulness of Narrow-band Imaging to Estimate the Superficial Spread of Squamous Cell Carcinomas in Oropharynx, Hypopharynx and Larynx
Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Oct 1, 2017
Actual Study Completion Date :
Oct 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Videoendoscopy with WL and NBI

The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).

Procedure: WL and NBI
For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).

Outcome Measures

Primary Outcome Measures

  1. Number of patients for whom superficial extension of the tumors has been increased by NBI. [4 minutes]

Secondary Outcome Measures

  1. Number of tumors upstaged. [4 minutes]

  2. Contribution of the NBI in the diagnosis of other synchronous locations. [4 minutes]

  3. Contribution of the NBI in the diagnosis of pre-neoplastic lesions. [4 minutes]

  4. Contribution of the NBI in the evaluation of surgical margins. [4 minutes]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients who can benefit a laryngoscopic exam under general anesthesia
Exclusion Criteria:
  • General anesthesia contra-indications

  • Local anesthesia allergy

  • Breast-feeding period or pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Toulouse Toulouse France 31059

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Sébastien VERGEZ, MD, PhD, University Hospital of Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT02035735
Other Study ID Numbers:
  • 13 203 02
First Posted:
Jan 14, 2014
Last Update Posted:
Dec 11, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 11, 2018